Cybin inc. provides corporate update

Toronto--(business wire)--cybin inc. (neo:cybn) (nyse american:cybn) (“cybin” or the “company”), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative psychedelic-based treatment options, provides a corporate update outlining access to capital and upcoming clinical milestones. “the second half of 2023 will be pivotal for cybin as we expect topline clinical data readouts from both our phase 1/2a trial of cyb003, our deuterated.
CYBN Ratings Summary
CYBN Quant Ranking